Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC-HTA study

Blood Pressure

Volumn 16, Issue 1, 2007, Pages 20-27

  Navarro, Jorge ^a   Redón, Josep ^b   Cea Calvo, Luis ^c   Lozano, José V ^d   Fernández Pérez, Cristina ^e   Bonet, Álvaro ^a   González Esteban, Jorge ^c  

^a Salvador Pau Health Care Center   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Medical affairs Merck sharp and Dohme ltd   (Spain)

^d Serreria 2 Health Center   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cardiovascular disease; Hypertension; Left ventricle hypertrophy; Metabolic syndrome; Risk

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; ELDERLY CARE; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; TARGET ORGAN;

AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SPAIN;

EID: 34247636234     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050701217817     Document Type: Article

References (41)

1. Lakka, H. M., Laaksonen, D. E., Lakka, T. A., Niskanen, L. K., Kumpusalo, E. and Tuomiletho, J. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288, pp. 2709-2716.
2. Chen, J., Muntner, P., Hamm, L. L., Jones, D. W., Batuman, V. and Fonseca, V. (2004) The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med, 140, pp. 167-174.
3. Malik, S., Wong, N. D., Franklin, S. S., Kamath, T. V., L'Italien, G. J. and Pio, J. R. (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular, and all causes in United States adults. Circulation, 110, pp. 1245-1250.
4. Iford, E. S., Giles, W. H. and Mokdad, A. H. (2004) Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care, 27, pp. 2444-2449.
5. Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., LHTi, K. and Nissen, M. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, pp. 683-689.
6. Alexander, C. M., Landsman, P. B., Teutssch, S. M. and Haffner, S. M. (2003) Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP): NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52, pp. 1210-1214.
7. Ascaso, J. F., Romero, P., Real, J. T., Lorente, R. I., Martinez-Valls, J. and Carmena, R. (2003) Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med, 14, pp. 101-106.
8. European Group for the Study of Insulin Resistance (EGIR) (2002) Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an Insulin resistance syndrome. Diabetes Metab, 28, pp. 364-376.
9. Leon, E. E. Alvarez, Barba, L. Ribas and Majem, L. Serra (2003) Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. [Prevalence of the metabolic syndrome in the population of Canary Islands, Spain]. Med Clin (Barc), 120, pp. 172-174.
10. Martinez-Larrad, M. T., Fernández-Pérez, C. and González-Sánchez, J. L. (2005) López A, Fernández-Álvarez J, Riviriego J, et al. Prevalencia del síndrome metabólico (criterios del ATP-III). Estudio de base poblacional en áreas rural y urbana de la provincia de Segovia. [Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia]. Med Clin (Barc), 125, pp. 481-486.
11. Alegría, E., Cordero, A., Laclaustra, M., Grima, A., León, M. and Casasnovas, J. A. (2005) Prevalencia del síndrome metabólico en población laboral española: Registro MESYAS. [Prevalence of metabolic syndrome in the Spanish working population: MESYAS registry]. Rev Esp Cardiol, 58, pp. 797-806.
12. Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G. and Bonadonna, R. C. (2003) Metabolic syndrome: Epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obesity, 27, pp. 1283-1289.
13. Rantala, A. O., Karma, H., Lilja, M., Savolainen, M. J., Reunanen, A. and Kesaniemi, Y. A. (1999) Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med, 245, pp. 163-174.
14. Bog-Hansen, E., Lindblad, U., Gullberg, B., Melander, A. and Rastam, L. (2003) Metabolic disorders associated with uncontrolled hypertension. Diabetes Obesity Metab, 5, pp. 379-387.
15. Schillaci, G., Pirro, M., Vaudo, G., Gemelli, F., Marchesi, S. and Porcellati, C. (2004) Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol, 43, pp. 1817-1822.
16. Martell, N., Mateo, J., Fernández, C., Fernández-Cruz, A. and Luque-Otero, M. (2004) Metabolic syndrome and insulin resistance in newly diagnosed hypertensives, treated hypertensives and normotensives. J Hypertens, 22, p. s368(A).
17. Cordero, A., Laclaustra, M., León, M., Casasnovas, J. A., Grima, A. and Najar, M. (2005) Factores de riesgo cardiovascular y síndrome metabólico asociados a la disfunción renal subclínica: Subanálisis del Registro MESYAS. [Cardiovascular risk factors and metabolic syndrome associated with subclinical renal failure]. Med Clin (Barc), 125, pp. 653-658.
18. Lozano, J. V., Redon, J., Cea-Calvo, L., Fernandez-Perez, C., Navarro, J. and Bonet, A. (2005) Evaluación del riesgo de un primer ictus en la población hipertensa española en atención primaria. Estudio ERIC-HTA. [Risk assessment for a first stroke in Spanish hypertensive population in primary care. The ERIC-HTA study]. Med Clin (Barc), 125, pp. 247-251.
19. Casale, P. N., Devereux, R. B., Kligfield, P., Eisenberg, R. R., Miller, D. H. and Chaudhary, B. S. (1985) Electrocardiographic detection of left ventricular hypertrophy: Development and prospective validation of improved criteria. J Am Coll Cardiol, 6, pp. 572-580.
20. Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A. and Steffes, M. W. (2003) National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med J, 139, pp. 137-147.
21. (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106, pp. 3143-3421.
22. Sattar, N., Gaw, A., Scherbakova, O., Ford, I., O'Reilly, D. S. and Haffner, S. M. (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108, pp. 414-419.
23. Girman, C. J., Rhodes, T., Mercuri, M., Pyorala, K., Kjekshus, J. and Pedersen, T. R. (2004) The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol, 93, pp. 136-141.
24. Wannamethee, S. G., Shaper, A. G., Lennon, L. and Morris, R. W. (2005) Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med, 165, pp. 2644-2650.
25. Goodpaster, Krishnaswami, S., Harris, T. B., Katsiaras, A., Kritchesvsky, S. B. and Simonsick, E. M. (2005) Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med, 165, pp. 777-783.
26. Lorenzo, C., Serrano-Rios, M., Martinez-Larrad, M. T., Gabriel, R., Williams, K. and Gonzalez-Villalpando, C. (2002) Prevalence of hypertension in Hispanic and non-Hispanic white populations. Hypertension, 39, pp. 203-208.
27. Neill, A. M. Mc, Rosamond, W. D., Girman, C. J., Golden, S. H., Schmidt, M. I. and East, H. E. (2005) The metabolic syndrome and 11-year risk of incidence cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care, 28, pp. 385-390.
28. Chinali, M., Devereux, R. B., Howard, B. V., Roman, M. J., Bella, J. N. and Liu, J. E. (2004) Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (The Strong Heart study). Am J Cardiol, 93, pp. 40-44.
29. Cuspidi, C., Meani, S., Fusi, V., Severgnini, B., Valerio, C. and Catini, E. (2004) Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens, 22, pp. 1991-1998.
30. Leoncini, G., Ratto, E., Viazzi, F., Vaccaro, V., Parodi, D. and Parodi, A. (2005) Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med, 257, pp. 454-460.
31. Mulè, G., Nardo, E., Cottone, S., Cusimano, P., Volpe, V. and Piazza, G. (2005) Influence of metabolic syndrome on hypertension-related target organ damage. J. Intern Med, 257, pp. 503-513.
32. Mule, G. and Cerasola, G. (2006) The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens, 8, pp. 195-201.
33. Foley, R. N., Wang, C. W. and Collins, A. J. (2005) Cardiovascular risk factor profiles and kidney function stage in the US general population: The NHANES III study. Mayo Clin Proc, 80, pp. 1270-1277.
34. Holmang, A., Yoshida, N., Jennische, E., Waldenstrom, A. and Bjorntorp, P. (1996) The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Invest, 26, pp. 973-978.
35. Verdecchia, P., Reboldi, G., Schillaci, G., Borgioni, C., Ciucci, A. and Telera, M. P. (1999) Circulating insulin and insulin growth factor 1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation, 100, pp. 1802-1807.
36. Lind, L., Andersson, P. E., Andren, B., Hanni, A. and Lithell, H. O. (1995) Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens, 13, pp. 433-438.
37. Rutter, M. K., Parise, H., Benjamin, E. J., Levy, D., Larson, M. G. and Meigs, J. B. (2003) Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex related differences in the Framingham Heart Study. Circulation, 107, pp. 448-454.
38. Parvanova, A. I., Trevisan, R., Iliev, I. P., Dimitrov, B. D., Vedovato, M. and Tiengo, A. (2006) Insulin resistance and microalbuminuria: A cross sectional, case control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes, 55, pp. 1456-1462.
39. Ninomiya, J. K., L'Italien, G., Criqui, M. H., Whyte, J. L., Gamst, A. and Chen, R. S. (2004) Association of tne metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination survey. Circulation, 109, pp. 42-46.
40. Ford, E. S. (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care, 28, pp. 1769-1778.
41. Alberti, K. G., Zimmet, P. and Shaw, J. (2006) Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med, 23, pp. 469-480.